StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Regeneron Pharma (REGN) ADVM Provides Gene Therapy Update - Jefferies
May 5, 2020 6:34 AM
Jefferies analyst Biren Amin reiterated a Buy rating and $657.00 price target on Regeneron Pharma (NASDAQ: REGN) after ADVM provided ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments